Qiagen NV | QIA - Cash And Equivalent


Qiagen NV reported $839M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
argenx SE USD 4.3B 808.71M Mar/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Dianthus Therapeutics USD 627.67M 576.58M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
IQVIA Holdings USD 1.95B 33M Mar/2026
Moderna USD 1.91B 687M Mar/2026
Organon & Co USD 1.12B 542M Mar/2026
Qiagen NV USD 839M 516.58M Dec/2025
Revvity USD 860.32M 59.54M Mar/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Viatris USD 1.8B 481.8M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026